FDA: Washington - The U.S. Food and Drug Administration estimates that the topical use of diclofenac may harm the liver. The manufacturer of a Voltaren ® gel was instructed to point in the product information.
on
* Communication from the FDA
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm193047.htm
* U.S. technical information to a Voltaren ® gel
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022122s006lbl.pdf
topical diclofenac preparations are a popular Means for external treatment of minor sports injuries such as bruises or sprains. Most users should consider ways that the drug might have after absorption through the skin, systemic side effects.
Possible consequences include the FDA severe liver injury. The announcement means we can disclose whether it actually occurred after topical application. The manufacturer of the Voltaren gel must be received in detail in the Summary of the risk.
Regular users are required to be determined within four to eight weeks after therapy, the transaminase.
© RME / aerzteblatt.de
0 comments:
Post a Comment